Also, fenofibrate, a PPARα agonist and drug that reduces progression of diabetic retinopathy in type 2 diabetes patients independent of its PPARα effects, suppressed retinal and choroidal neovascularization in mice overexpressing CYP2C8 in endothelial cells and reduced plasma levels of the CYP2C8 metabolite 19,20-EDP. Here, PPARA is linked to diabetic retinopathy.